drugset / Trial / NCT04705844
Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)
Phase 3
Withdrawn
Alachua Government Services, Inc.
Chemical, Biological, Radiological, and Nuclear Medical · collabPharm-Olam, LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19
Timeline
- Start
- 2021-09
- Primary completion
- 2022-09
- Completion
- 2022-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 160 mg | Subcutaneous |
Indications
No indication recorded.